<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02451774</url>
  </required_header>
  <id_info>
    <org_study_id>IICIA -PTX02</org_study_id>
    <nct_id>NCT02451774</nct_id>
  </id_info>
  <brief_title>Pentoxifylline In Pediatric Acute Lymphoblastic Leukemia During Induction</brief_title>
  <acronym>PTX-II</acronym>
  <official_title>SAFETY AND EFFICACY OF PENTOXIFYLLINE VERSUS PLACEBO ADMINISTERED AS APOPTOSIS INDUCTOR DURING REMISSION INDUCTION PHASE OF PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ramón Óscar González-Ramella, Ph.D</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Investigacion en Cancer de la Infancia y la Adolescencia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Civil Juan I. Menchaca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro de Investigacion Biomedica de Occidente</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Guadalajara</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent advances in acute lymphoblastic leukemia treatment are based on a cytotoxic drug
      combination. Measurement of minimal residual disease in bone marrow samples at day 14 of
      treatment is the most powerful early predictive indicator of further relapse, and it can be
      applied practically to all patients with acute lymphoblastic leukemia. Even more so, it has
      been observed that patients who present negative minimal residual disease in bone marrow
      samples at day 7 during induction have a better prognosis than those achieving this at day
      14.

      Relapse represents the main cause of treatment failure that related in the extreme with
      resistance to apoptosis, defining the latter as the principal mechanism of programmed cell
      death; it is also related with the induction of leukemic cells to senescent arrest.

      Pentoxifylline is a methyl-xanthine byproduct considered an unspecific inhibitor of
      phosphodiesterase. It inhibits nuclear factor-kappa-beta activation by different mechanisms
      and stimulates apoptosis induced by different drugs; thus, it can optimize the antineoplastic
      effect of actual treatments in order to increase the apoptosis of leukemic cells. This effect
      might improve the prognosis of these patients.

      Evaluate the safety and effect of Pentoxifylline together with antineoplastic drugs in order
      to study increased apoptosis and decreased senescence during the remission induction phase in
      pediatric patients with newly diagnosed acute lymphoblastic leukemia. To achieve this
      propose, we will divide patients in two groups, who will receive pentoxifylline or placebo
      depending on the group, in addition to conventional treatment according to the protocol
      standard chemotherapy schema for pediatric patients with acute lymphoblastic leukemia at our
      institution during the remission induction phase. In addition, we will test whether the study
      group exerts an impact on reaching remission earlier as compared with the control group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be controlled, double-blind clinical trial versus placebo, with random
      assignment to evaluate the effect of pentoxifylline on apoptosis and senescence of leukemic
      blasts from remission induction in pediatric patients with newly diagnosed acute
      lymphoblastic leukemia, as well as to address pentoxifylline efficacy and safety in this
      group of patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apoptosis measure by Flow Cytometry</measure>
    <time_frame>Up to 28 days after initiation of chemotherapy for remission induction</time_frame>
    <description>Percentage of apoptotic cells by Flow Cytometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Senescence measure by Flow Cytometry</measure>
    <time_frame>Up to 28 days after initiation of chemotherapy for remission induction.</time_frame>
    <description>Percentage of senescent blasts by Flow Cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety measure by Common Terminology Criteria for Adverse Events version 4.0</measure>
    <time_frame>Evaluate frequency adverse events with pentoxifylline up to 6 weeks</time_frame>
    <description>Percentage of adverse events grading table is a list of common terms and severity (intensity) of parameters used to describe adverse events occurring in Common Terminology Criteria for Adverse Events version 4.0</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Gene expression measure by Microarray and Semi-quantitative Polymerase Chain Reaction.</measure>
    <time_frame>Up to 28 days after initiation of chemotherapy for remission induction.</time_frame>
    <description>Fold change by microarray and Semi-quantitative Polymerase Chain Reaction.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Pentoxifylline Plus Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pentoxifylline: 10-20 milligrams per kilogram, doses daily by oral, for 30 days.
Chemotherapy: Prednisone, Vincristine, Daunorubicin, L-asparaginase, Cyclophosphamide, Cytarabine, 6-Mercaptopurine, Methotrexate, Hydrocortisone and Cytarabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Plus Chemotherapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: double blind period, one doses daily for 30 days. Chemotherapy: Prednisone, Vincristine, Daunorubicin, L-asparaginase, Cyclophosphamide, Cytarabine, 6-Mercaptopurine, Methotrexate, Hydrocortisone and Cytarabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentoxifylline Plus Chemotherapy</intervention_name>
    <description>Pentoxifylline 10 to 20 milligrams per kilogram, daily, for up to 32 days Chemotherapy: Prednisone 40 milligrams per square meter per day, orally, day 5-32. Vincristine 1.5 milligrams per square meter per week, intravenously, day 5, 12, 19, 26. Daunorubicin 25 milligrams per square meter per week, intravenously, days 5; 12. L-asparaginase 10,000 units for square meter, intramuscular, days 6, 8, 10, 12, 14, 16, 19, 21, 23. Cyclophosphamide 1000 milligrams per square meter per dose intravenously, day 26. Cytarabine 75 milligrams per square meter per dose intravenously, days 27-30, 34-37. 6-Mercaptopurine 60 milligrams per square meter per dose, orally, days 26-39, Mix: Methotrexate 8-12 milligrams, Hydrocortisone 16-24 milligrams and Cytarabine 24-36 milligrams, intrathecal, day 19.</description>
    <arm_group_label>Pentoxifylline Plus Chemotherapy</arm_group_label>
    <other_name>Oxpentifylline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Plus Chemotherapy</intervention_name>
    <description>Placebo daily, for up to 32 days Chemotherapy: Prednisone 40 milligrams per square meter per day, orally, day 5-32. Vincristine 1.5 milligrams per square meter per week, intravenously, day 5, 12, 19, 26. Daunorubicin 25 milligrams per square meter per week, intravenously, days 5; 12. L-asparaginase 10,000 units for square meter, intramuscular, days 6, 8, 10, 12, 14, 16, 19, 21, 23. Cyclophosphamide 1000 milligrams per square meter per dose intravenously, day 26. Cytarabine 75 milligrams per square meter per dose intravenously, days 27-30, 34-37. 6-Mercaptopurine 60 milligrams per square meter per dose, orally, days 26-39, Mix: Methotrexate 8-12 milligrams, Hydrocortisone 16-24 milligrams and Cytarabine 24-36 milligrams, intrathecal, day 19.</description>
    <arm_group_label>Placebo Plus Chemotherapy</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pediatric and teenaged patients of both genders ≤18 years of age with newly diagnosed
             acute lymphoblastic leukemia in accordance with French-American-British criteria and
             under immunophenotypical classification and paired within the risk-classification
             group.

          -  Patients with ≥20 kg of weight at the time of treatment assignment.

          -  Patients who are able to swallow the medicine

          -  Patients agreeing to enter the protocol by the signing of informed consent by the
             parent

          -  Patients who could give their assent to enter the protocol

          -  The parent or guardian must be able to read.

        Exclusion Criteria:

          -  Patients with treatment adherence of ≥80 percent

          -  Patients or their parents who decide to abandon the study or who withdraw consent for
             participation

          -  Patients who present grade III or higher adverse event.

          -  Patients previously treated with chemotherapy and/or radiotherapy

          -  History of peptic acid disease or gastrointestinal bleeding

          -  Known pentoxifylline intolerance and general intolerance to xanthine, caffeine or
             theophylline

          -  Patients in treatment with anticoagulants, Cimetidine, Ciprofloxacin, or Theophylline

          -  Patients with Down syndrome

          -  Patients with several bleeding or extensive retinal hemorrhage, several cardiac
             arrhythmias (paroxysmal supraventricular tachycardia, congenital atrioventricular
             block, arrhythmias associated with congenital heart disease, digital poisoning, and
             patients after cardiac surgery, hypoxia, hypercapnia, and electrolyte disturbances)

          -  Patients with hypotension

          -  Several liver failures

          -  Bleeding diathesis (for bleeding disorders or anticoagulant medication)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramón O. Gonzalez Ramella, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de Investigacion de Cancer de la Infancia y la Adolescencia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Monzerrat Pardo Zepeda, MD</last_name>
    <phone>+5213311946817</phone>
    <email>monzepardo@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fernando A. Sanchez Zubieta, MD</last_name>
    <phone>+5213314663092</phone>
    <email>fernandos59@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Civil de Guadalajara &quot;Dr. Juan I. Menchaca&quot;</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramon O Gonzalez Ramella, PhD</last_name>
      <phone>5213331719826</phone>
      <email>glezramella@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Fabiola P Medina Barajas, PhD</last_name>
      <phone>5213313461917</phone>
      <email>favyri@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <results_reference>
    <citation>Makishima H, Visconte V, Sakaguchi H, Jankowska AM, Abu Kar S, Jerez A, Przychodzen B, Bupathi M, Guinta K, Afable MG, Sekeres MA, Padgett RA, Tiu RV, Maciejewski JP. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood. 2012 Apr 5;119(14):3203-10. doi: 10.1182/blood-2011-12-399774. Epub 2012 Feb 9.</citation>
    <PMID>22323480</PMID>
  </results_reference>
  <results_reference>
    <citation>Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood. 2012 Jan 5;119(1):34-43. doi: 10.1182/blood-2011-04-347872. Epub 2011 Nov 15.</citation>
    <PMID>22086414</PMID>
  </results_reference>
  <results_reference>
    <citation>Pérez-Saldivar ML, Fajardo-Gutiérrez A, Bernáldez-Ríos R, Martínez-Avalos A, Medina-Sanson A, Espinosa-Hernández L, Flores-Chapa Jde D, Amador-Sánchez R, Peñaloza-González JG, Alvarez-Rodríguez FJ, Bolea-Murga V, Flores-Lujano J, Rodríguez-Zepeda Mdel C, Rivera-Luna R, Dorantes-Acosta EM, Jiménez-Hernández E, Alvarado-Ibarra M, Velázquez-Aviña MM, Torres-Nava JR, Duarte-Rodríguez DA, Paredes-Aguilera R, Del Campo-Martínez Mde L, Cárdenas-Cardos R, Alamilla-Galicia PH, Bekker-Méndez VC, Ortega-Alvarez MC, Mejia-Arangure JM. Childhood acute leukemias are frequent in Mexico City: descriptive epidemiology. BMC Cancer. 2011 Aug 17;11:355. doi: 10.1186/1471-2407-11-355.</citation>
    <PMID>21846410</PMID>
  </results_reference>
  <results_reference>
    <citation>Belson M, Kingsley B, Holmes A. Risk factors for acute leukemia in children: a review. Environ Health Perspect. 2007 Jan;115(1):138-45. Review. Erratum in: Environ Health Perspect. 2010 Sep;118(9):A380.</citation>
    <PMID>17366834</PMID>
  </results_reference>
  <results_reference>
    <citation>Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008 Mar 22;371(9617):1030-43. doi: 10.1016/S0140-6736(08)60457-2. Review.</citation>
    <PMID>18358930</PMID>
  </results_reference>
  <results_reference>
    <citation>Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011 Feb 10;29(5):551-65. doi: 10.1200/JCO.2010.30.7405. Epub 2011 Jan 10. Review. Erratum in: J Clin Oncol. 2011 Dec 20;29(36):4847.</citation>
    <PMID>21220611</PMID>
  </results_reference>
  <results_reference>
    <citation>Wong RS. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res. 2011 Sep 26;30:87. doi: 10.1186/1756-9966-30-87. Review.</citation>
    <PMID>21943236</PMID>
  </results_reference>
  <results_reference>
    <citation>Herr I, Debatin KM. Cellular stress response and apoptosis in cancer therapy. Blood. 2001 Nov 1;98(9):2603-14. Review.</citation>
    <PMID>11675328</PMID>
  </results_reference>
  <results_reference>
    <citation>Campisi J. Aging, cellular senescence, and cancer. Annu Rev Physiol. 2013;75:685-705. doi: 10.1146/annurev-physiol-030212-183653. Epub 2012 Nov 8. Review.</citation>
    <PMID>23140366</PMID>
  </results_reference>
  <results_reference>
    <citation>Sankari SL, Masthan KM, Babu NA, Bhattacharjee T, Elumalai M. Apoptosis in cancer--an update. Asian Pac J Cancer Prev. 2012;13(10):4873-8. Review.</citation>
    <PMID>23244073</PMID>
  </results_reference>
  <results_reference>
    <citation>Chauhan PS, Bhushan B, Singh LC, Mishra AK, Saluja S, Mittal V, Gupta DK, Kapur S. Expression of genes related to multiple drug resistance and apoptosis in acute leukemia: response to induction chemotherapy. Exp Mol Pathol. 2012 Feb;92(1):44-9. doi: 10.1016/j.yexmp.2011.09.004. Epub 2011 Oct 19.</citation>
    <PMID>22037714</PMID>
  </results_reference>
  <results_reference>
    <citation>Reuter S, Gupta SC, Kannappan R, Aggarwal BB. WITHDRAWN: Evidence for the critical roles of NF-κB p65 and specificity proteins in the apoptosis-inducing activity of proteasome inhibitors in leukemia cells. Biochim Biophys Acta. 2012 Jan 10. [Epub ahead of print]</citation>
    <PMID>22265847</PMID>
  </results_reference>
  <results_reference>
    <citation>Hernandez-Flores G, Ortiz-Lazareno PC, Lerma-Diaz JM, Dominguez-Rodriguez JR, Jave-Suarez LF, Aguilar-Lemarroy Adel C, de Celis-Carrillo R, del Toro-Arreola S, Castellanos-Esparza YC, Bravo-Cuellar A. Pentoxifylline sensitizes human cervical tumor cells to cisplatin-induced apoptosis by suppressing NF-kappa B and decreased cell senescence. BMC Cancer. 2011 Nov 10;11:483. doi: 10.1186/1471-2407-11-483.</citation>
    <PMID>22074157</PMID>
  </results_reference>
  <results_reference>
    <citation>Armstrong SA, Look AT. Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol. 2005 Sep 10;23(26):6306-15. Review.</citation>
    <PMID>16155013</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2015</study_first_submitted>
  <study_first_submitted_qc>May 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2015</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Guadalajara</investigator_affiliation>
    <investigator_full_name>Ramón Óscar González-Ramella, Ph.D</investigator_full_name>
    <investigator_title>PhD in immunology</investigator_title>
  </responsible_party>
  <keyword>pediatric</keyword>
  <keyword>apoptosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>Pentoxifylline</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

